Multiplex Assay Kit for Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) Homo sapiens (Human) Multiplex ELISA

ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor

(Note: Up to 8-plex in one testing reaction)

Add to Cart Distributors
Overview
Properties
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Multiplex Assay Kit for Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) Packages (Simulation)
  • Multiplex Assay Kit for Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) Results demonstration
  • LMA746Hu.jpg Typical Standard Curve
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Recovery

Matrices listed below were spiked with certain level of recombinant Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 96-104 101
EDTA plasma(n=5) 83-95 91
heparin plasma(n=5) 99-105 102
sodium citrate plasma(n=5) 93-105 101

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 80-105% 93-103% 92-99% 85-104%
EDTA plasma(n=5) 80-96% 89-99% 84-91% 81-101%
heparin plasma(n=5) 92-102% 85-101% 84-98% 93-101%
sodium citrate plasma(n=5) 83-93% 78-103% 93-101% 97-105%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:FGF23) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

Multiplex Assay Kit for Fibroblast Growth Factor 23 (FGF23) ,etc. by FLIA (Flow Luminescence Immunoassay)

Test principle

Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.

Giveaways

Citations

  • Prognostic impact of renal function in precapillary pulmonary hypertensionPubmed: 24011362
  • FGF-23 associated with the progression of coronary artery calcification in hemodialysis patientsPubmed: 24180481
  • Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral MetabolismPubmed: 23623649
  • Prognostic impact of renal function in precapillary pulmonary hypertension.Pubmed:24011362
  • Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growthPubmed:25639729
  • Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrinaPubMed: 26394828
  • An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic CancerPubMed: 26266370
  • Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique?PubMed: 26069069
  • High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23Pubmed:27326766
  • Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model ofDistal Nephron Salt Wasting.pubmed:27442254
  • Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantationpublication:312592751
  • Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patientsissn:2394-2916
  • ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder.pubmed:29056164
  • Effect of cross-linked chitosan iron (III) on vascular calcification in uremic ratsPubmed:29763365
  • Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivityPubmed:29677623
  • Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill childrenPubmed:29907141
  • Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention StudyPubmed:29608553
  • Disconnection of pulmonary and systemic arterial stiffness in COPDPubmed:29881265
  • Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patientsPubmed:29970732
  • High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney diseasePubmed: 30189026
  • Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinomaPubmed: 30334297
  • Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis PatientsPubmed: 30847765
  • Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseasesPubmed: 31407857
  • PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTSPubmed: 28797410
  • Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney diseasePubmed: 31696838
  • MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7Pubmed: 31918268
  • Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis?
  • THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS
  • THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ¡­
  • The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) ConcentrationsPubmed:35665817
  • Genetic and clinical profile of patients with hypophosphatemic ricketsPubmed:35738466
  • Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease

Recommend products